TTPH Tetraphase Pharmaceuticals, Inc

7.25
-0.14  -2%
Previous Close 7.39
Open 7.40
Price To book 2.34
Market Cap 275.18M
Shares 37,956,000
Volume 251,172
Short Ratio 2.39
Av. Daily Volume 620,006

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial initiation announced January 17, 2016.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
Phase 3 data due 3Q 2017.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)

Latest News

  1. Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017
  2. Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : May 15, 2017
  3. Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : May 12, 2017
  4. Tetraphase reports 1Q loss
  5. Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights
  6. Implied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options
  7. Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  8. Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
  9. ​These 5 Mass. biotechs are getting $12M to fight ‘superbugs’
  10. Tetraphase Pharmaceuticals’ TP-6076 Selected by CARB-X to Receive $4 Million in Research Funding
  11. ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : March 27, 2017
  12. Tetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  13. Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  14. 5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts
  15. Are Options Traders Betting on a Big Move in Tetraphase (TTPH) Stock?
  16. Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  17. Today's Research Reports on Biotech Stocks to Watch: Inotek Pharmaceuticals and Tetraphase Pharmaceuticals
  18. Tetraphase Pharmaceuticals Inc Is Climbing Again Today -- Here's Why
  19. Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones